ON
← Back to feed
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
United States🩺 HealthCenter

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The U.S. Food and Drug Administration has rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso. In a letter to the companies, FDA regulators stated that the drug failed to demonstrate a survival benefit for patients, despite showing efficacy in slowing disease progression. The agency concluded that the lack of improved life expectancy did not justify a favorable benefit-risk profile necessary for approval. This decision represents a significant regulatory setback for Summit Therapeutics, which manages the drug's development outside of China, though industry observers had anticipated potential hurdles.

2 reports

MarketWatch logoMarketWatchIndependentCenter
The FDA declined to approve one of biotech’s most closely watched cancer drugs

The FDA has rejected the approval of a highly anticipated cancer drug developed by Summit Therapeutics. The agency stated that the drug, which targets lung cancer, must demonstrate that it can extend patients' lives before it can be approved. This decision highlights the stringent requirements set by regulatory bodies for new treatments, especially those targeting serious conditions like lung cancer. The rejection could delay patient access to the drug while Summit Therapeutics works to address the FDA's concerns.

Bias read (Center): The article presents the FDA's decision neutrally, focusing on the regulatory requirement for the drug to show improved survival rates without apparent bias toward either the pharmaceutical company or the regulatory body.

STAT News logoSTAT NewsIndependentCenter
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The U.S. Food and Drug Administration has rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso. In a letter to the companies, FDA regulators stated that the drug failed to demonstrate a survival benefit for patients, despite showing efficacy in slowing disease progression. The agency concluded that the lack of improved life expectancy did not justify a favorable benefit-risk profile necessary for approval. This decision represents a significant regulatory setback for Summit Therapeutics, which manages the drug's development outside of China, though industry observers had anticipated potential hurdles.

Bias read (Center): The article relies exclusively on official FDA communications and corporate announcements, using neutral terminology like 'regulatory setback' without injecting partisan commentary or speculative motives.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories